Drugs / IRX-101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT05747430 | Feb 2023 → Mar 2025 | retinal disorder | iRenix Medical, Inc. | Completed | Met primary |
| Phase 32 trials | ||||||
| Phase 3 | NCT05750589 | Sep 2026 → Jan 2027 expected | retinal disorder | iRenix Medical, Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05127525 | Nov 2021 → Jan 2022 | angle-closure glaucoma, diabetic macular edema, occlusion of tributary of retinal vein | iRenix Medical, Inc. | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-08 | Tarsus Pharmaceuticals, Inc. | Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101 tarsusrx.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IRX-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05747430 ↗ |
| Route | Topical | “IRX-101 drops instilled prior to intravitreal injection” NCT05127525 ↗ |